News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
GenVec Inc. Says Cancer Therapy Increases Survival; Shares Up
May 29, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
May 29 (Reuters) - Genvec Inc said its gene therapy product, TNFerade, increased survival of patients with esophageal cancer longer than comparable studies, sending its shares up 11 percent before the bell.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
MORE ON THIS TOPIC
Infectious disease
Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25
July 15, 2025
·
4 min read
·
Tristan Manalac
Obesity
Hengrui’s Dual GLP-1/GIP Elicits 17.7% Weight Loss in Phase III
July 15, 2025
·
2 min read
·
Dan Samorodnitsky
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
·
6 min read
·
Lori Ellis
Cardiovascular disease
AstraZeneca’s Baxdrostat Pushes Blood Pressure Lower in Phase III Trial
July 14, 2025
·
1 min read
·
Dan Samorodnitsky
